Seraxis is bringing transformative cures to the millions of T1D and insulin-requiring T2D patients who all struggle with the management and life-threatening complications of their disorder. Seraxis’ islet replacements are manufactured from a best-in-class stem cell line derived from a single highly compatible human donor pancreas. Unlike ECs and iPSCs, these stem cells preferentially re-differentiate into pure pancreatic clusters containing all the endocrine cells of the native pancreatic islet as to offer safety, potency, and manufacturing advantages. Seraxis’ proof-of-concept pancreatic cluster, SR-02, will enter US clinical testing in 4Q24 in T1D patients with severe recurrent hypoglycemia. Also in the pipeline is SR-03, a genetically-modified allo-compatible version of the Seraxis SR-02 for implantation without IS for the broader insulin-requiring diabetes population. Seraxis is backed by Frazier Life Sciences, Polaris Partners, Eli Lilly, the T1D Fund and others.